Thalidomide to Patients With Previously Untreated Multiple Myeloma
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Sep 20, 2005
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Thalidomide has recently emerged as an effective treatment for patients with myeloma refractory to conventional chemotherapy. So far only limited experience is available on thalidomide for newly diagnosed myeloma. Therefore the Nordic Myeloma Study Group decided to perform a trial comparing traditional melphalan-prednisone therapy with melphalan-prednisone + thalidomide/placebo. The study design is a multicentre double-blind randomised placebo-controlled trial. Mainly patients \>65 years of age will be included since patients \<65 years will be treated with high dose chemotherapy with autol...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with multiple myeloma in need of treatment
- Exclusion Criteria:
- • Previous treatment against multiple myeloma
- • Need of high dose chemotherapy with autologous stem cell support
- • Women in fertile age
- • Psychiatric disease or mental reduction leading to lack of cooperation
- • Lack of consent
- • Life expectancy below 3 months
- • Active cancer of other etiology
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Anders Waage, MD
Study Chair
Department of Haematology, St. Olavs hospital/NTNU, N-7006 Trondheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials